The Estée Lauder Companies Fully Establishes Its “One ELC” Operating Model and Reaches Milestone in Its Profit Recovery and Growth Plan
1.4.2026 23:00:00 CEST | Business Wire | Press release
WPP Appointed First-Ever Global Media Partner, Unifying Media Execution Worldwide“One ELC” Operating Model Is Transforming How the Company Operates at Scale
The Estée Lauder Companies Inc. (NYSE: EL) today announced WPP as its first-ever global media partner, marking a significant advancement of its One ELC operating model, a scalable system designed to operate faster, execute with greater discipline, and drive growth. In fully establishing One ELC, the Company also reached a significant milestone in its Profit Recovery and Growth Plan’s (PRGP) Restructuring Program — a key action plan priority of Beauty Reimagined.
Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies, said, “With the appointment of WPP as our first-ever global media partner, our One ELC operating model is now fully established. This more unified and scalable system will enable us to be faster, more agile and efficient, and support unlocking additional growth. Together with our execution progress, we are confident that we are on a trajectory to deliver sustainable, profitable long-term growth.”
de La Faverie added, “Building on our strong fiscal 2026 first half results, which included increased consumer-facing investments to restore sustainable sales growth, today we announced an important milestone in the Profit Recovery and Growth Plan’s Restructuring Program. We have now approved initiatives to achieve the high-end of the target gross savings range and affirmed we are on track to realize the vast majority of PRGP’s full run-rate benefits in fiscal 2027. The PRGP has instilled a strong sense of cost discipline into our organization that is now embedded in our ways of working.”
Advancing a New Operating Foundation
The Company has fundamentally changed how it operates and now has the foundational pieces in place to complete its transformation. At the center of this is the Company’s One ELC operating model, an integrated system built on three elements: One Team, One Culture, and One Operating Ecosystem.
One Team, deployed swiftly in July 2025 to simplify the organization with fewer layers and silos, clearer ownership, and faster decision making.
One Culture, introduced in February 2026, to reinforce how teams work every day, grounded in accountability, bold, entrepreneurial thinking, and agility.
One Operating Ecosystem, built over the last year and now fully in place, brings together shared platforms, data, and strategic partners to enable consistent, scalable, and effective execution across brands, regions, and functions.
Establishing a Unified Global Media Model
As a core component of its One Operating Ecosystem within One ELC, the Company has appointed WPP as its first global media partner, establishing a unified, enterprise-led approach to media buying designed to enable greater scale, precision, and impact.
The Company is moving from a decentralized regional media structure to a connected global system powered by data, technology, and AI. This model strengthens the Company’s ability to generate and capture demand while improving media effectiveness and efficiency at scale and at speed.
Aude Gandon, Chief Digital and Marketing Officer, The Estée Lauder Companies, said, “Today, beauty is discovered and experienced across a constantly evolving mix of platforms. To lead in this environment, we are building a connected, AI-enabled media system that brings brand building and performance together at global scale. Partnering with WPP strengthens our ability to invest with greater precision, move with greater speed, and deliver stronger, more measurable returns, while keeping creativity and brand leadership at the center of everything we do.”
Delivering a Connected Ecosystem with Strategic Partners
With WPP’s appointment, the Company’s One Operating Ecosystem is now in place and brings together a coordinated set of best-in-class strategic partners to modernize and scale how it operates globally.
Accenture is transforming shared services through the Company’s Enterprise Business Services (EBS) model, driving standardization, efficiency, and scalability across core functions. The Company has designed EBS and begun transitioning services, with the model on track to be fully in place before the end of calendar year 2026.
Shopify powers the Company’s global direct-to-consumer omnichannel experience, creating a modern and unified commerce foundation. Initial implementation with TOM FORD BEAUTY’s brand.com in the U.S. has already delivered improved sales, conversion, and average order value performance — all encouraging signs as the foundation scales. Following the initial implementation phase, the Company expects to have launched 50% of the in-scope direct-to-consumer business by the end of calendar year 2026.
By partnering with best-in-class organizations, the Company is transitioning from a fragmented data landscape to a more unified one. This will create a scalable foundation for real-time insights, a single consumer view, and more effective activation across brands and markets.
Delivering Against the Profit Recovery and Growth Plan
Since expanding the Restructuring Program when it introduced Beauty Reimagined in February 2025, the Company has taken decisive actions to reshape its cost structure and operations, allowing for increased consumer-facing investments. As of March 31, 2026, the Company has approved initiatives expected to deliver total gross benefits at the high end of its targeted range of $0.8 billion to $1.0 billion, a portion of which has been and will continue to be reinvested in consumer-facing initiatives, with expected total charges at the mid-point of the estimated range of $1.2 billion to $1.6 billion.
With a line of sight to additional gross benefits, all business case approvals for the Restructuring Program are still expected to be made by June 30, 2026. This progress reflects disciplined delivery against clearly defined priorities and has supported the Company’s ability to reinvest for growth. The Company expects execution of the PRGP to be substantially complete by the end of fiscal 2027 and affirmed that the vast majority of PRGP’s full run-rate benefits, including its Restructuring Program, are to be achieved during fiscal 2027.
Cautionary Note Regarding Forward-Looking Statements
The forward-looking statements contained herein, including those relating to our expectations regarding restructuring and other charges, involve risks and uncertainties. Factors that could cause actual results to differ materially from those forward-looking statements include current economic and other conditions in the global marketplace, actions by retailers and consumers, competition, The Estée Lauder Companies’ ability to successfully implement its long-term strategic plan, and those factors described in The Estée Lauder Companies’ Annual Report on Form 10-K for the fiscal year ended June 30, 2025.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.
About WPP
WPP is the trusted growth partner for the world’s leading brands. We unite cutting-edge media intelligence and data solutions, world-class creativity, next-generation production, transformative enterprise solutions and expert strategic counsel in a single company – powered by exceptional talent and our agentic marketing platform, WPP Open, to help our clients navigate change, capture opportunity and deliver transformational growth. For more information, visit wpp.com.
About WPP Media
WPP Media is WPP’s global media collective. In a world where media is everywhere and in everything, it brings the best platform, people, and partners together to create limitless opportunities for growth. For more information, visit wppmedia.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260401678161/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom